Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 Read more about Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition Read more about Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition
Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meet Read more about Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meet
Agios Appoints Tsveta Milanova as Chief Commercial Officer Read more about Agios Appoints Tsveta Milanova as Chief Commercial Officer
Agios to Participate in December Investor Conference Read more about Agios to Participate in December Investor Conference
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients Read more about PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition Read more about Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition
Agios Reports Business Highlights and Third Quarter 2022 Financial Results Read more about Agios Reports Business Highlights and Third Quarter 2022 Financial Results
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty Read more about Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022 Read more about Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022